Sarah Sherlock

Sarah Sherlock is currently the Head of Clinical Imaging in Early Clinical Development at AstraZeneca. With extensive experience in incorporating medical imaging into clinical trials, they previously held multiple roles at Pfizer, including Director of Clinical and Translational Imaging and Senior Director of Clinical Imaging. Sarah developed biocompatible nanomaterials during their Ph.D. studies at Stanford University, where they also participated in research focused on cancer therapies. They have a broad understanding of imaging biomarkers, imaging vendor oversight, and clinical development.